Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA + anti-CD19 CAR-T cells
- Development stage
- Preclinical
- Lead developer
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-BCMA + anti-CD19 CAR-T cells are a dual-targeted chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of plasma cell malignancies, including multiple myeloma and plasma cell leukemia. By simultaneously targeting B-cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells, and CD19, which is expressed on B-cell lineage cells and potentially on myeloma stem cells, this therapy aims to provide a more comprehensive anti-tumor response and reduce the likelihood of relapse through antigen escape. The Affiliated Hospital of Xuzhou Medical University has initiated clinical trials (e.g., ChiCTR2000033567) to evaluate the safety and efficacy of this dual-target construct in patients with refractory or recurrent plasma cell tumors and related lymphoid diseases.
- Other names
- anti-BCMA and anti-CD19 dual-target CAR-T cellsBCMA/CD19 dual CAR-Tanti-BCMA and anti-CD19 double targets CAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-BCMA + anti-CD19 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA + anti-CD19 CAR-T cells.